Alzheimer's disease

R&D

A closer look at how clinical trials for Alzheimer’s have evolved and what this means for patients and sites, with Medidata and Cogstate.

News

Lilly has launched a new awareness campaign in the US, focusing on dementia, and named A-list actress Julianne Moore to front it.

News

Before it has even launched, Eisai has filed to widen subcutaneous Leqembi's label to include starting as well as maintenance dosing in Alzheimer's.

News

A three-minute test could help diagnose people at risk of developing dementia, spotting signs of cognitive decline years before other approaches.

News

Eisai and Biogen get FDA approval for subcutaneous Leqembi. Will it help stave off growing competition from Lilly's Kisunla in Alzheimer's treatment?

News

Germany and Austria are the first countries in the EU to see the launch of Leqembi, Eisai and Biogen's much-delayed treatment for Alzheimer's.